EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma

Daniel P de Bruyn, Natasha M van Poppelen, Tom Brands, Susanne C van den Boom, Ellis Eikenboom, Anja Wagner, Monique M van Veghel-Plandsoen, Geert Geeven, Berna Beverloo, Caroline M van Rij, Robert M Verdijk, Nicole C Naus and 5 more

Investigative Opthalmology & Visual Science · 2024

DOI: 10.1167/iovs.65.2.11 ↗

At a glance

Journal article in Investigative Opthalmology & Visual Science, 2024. Written by Daniel P de Bruyn and 16 co-authors. Institution: Department of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands. Major MEDLINE topics: Circulating Tumor DNA, Melanoma, Uveal Neoplasms. Cited 19 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Purpose

Uveal melanoma (UM) has a high propensity to metastasize. Prognosis is associated with specific driver mutations and copy number variations (CNVs), but limited primary tumor tissue is available for molecular characterization due to eye-sparing irradiation treatment. This study aimed to assess the rise in circulating tumor DNA (ctDNA) levels in UM and evaluate its efficacy for CNV-profiling of patients with UM.

Methods

In a pilot study, we assessed ctDNA levels in the blood of patients with UM (n = 18) at various time points, including the time of diagnosis (n = 13), during fractionated stereotactic radiotherapy (fSRT) treatment (n = 6), and upon detection of metastatic disease (n = 13). Shallow whole-genome sequencing (sWGS) combined with in silico size-selection was used to identify prognostically relevant CNVs in patients with UM (n = 26) from peripheral blood retrieved at the time of diagnosis (n = 9), during fSRT (n = 5), during post-treatment follow-up (n = 4), metastasis detection (n = 6), and metastasis follow-up (n = 4).

Results

A total of 34 patients had blood analyzed for ctDNA detection (n = 18) and/or CNV analysis (n = 26) at various time points. At the time of diagnosis, 5 of 13 patients (38%) had detectable ctDNA (median = 0 copies/mL). Upon detection of metastatic disease, ctDNA was detected in 10 of 13 patients (77%) and showed increased ctDNA levels (median = 24 copies/mL, P 0.05). The ctDNA fractions were undetectable to low in localized disease, and sWGS did not elucidate chromosome 3 status from blood samples. However, in 7 of 10 (70%) patients with metastases, the detection of chromosome 3 loss corresponded to the high metastatic-risk class.

Conclusions

The rise in ctDNA levels observed in patients with UM harboring metastases suggests its potential utility for CNV profiling. These findings highlight the potential of using ctDNA for metastasis detection and patient inclusion in therapeutic studies targeting metastatic UM.

Subjects

MeSH terms (MEDLINE)

Circulating Tumor DNAMelanomaUveal NeoplasmsHumansDNA Copy Number VariationsPilot ProjectsBiomarkersUveal Melanoma

Substances

Circulating Tumor DNABiomarkers

Authors and institutions

  • Department of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands.
  • Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Radiation Oncology, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Pathology, Section Ophthalmic Pathology, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Pathology, LUMC, Leiden, The Netherlands.

Cite

APA

de Bruyn, D. P., van Poppelen, N. M., Brands, T., van den Boom, S. C., Eikenboom, E., Wagner, A., van Veghel-Plandsoen, M. M., Geeven, G., Beverloo, B., van Rij, C. M., Verdijk, R. M., Naus, N. C., Bagger, M. M., Kiilgaard, J. F., de Klein, A., Brosens, E., & Kiliç, E. (2024). Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.65.2.11

Vancouver

de Bruyn DP, van Poppelen NM, Brands T, van den Boom SC, Eikenboom E, Wagner A, et al. Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma. Investigative Opthalmology & Visual Science. 2024. doi:10.1167/iovs.65.2.11

BibTeX
@article{deBruyn2024,
  author = {de Bruyn, Daniel P and van Poppelen, Natasha M and Brands, Tom and van den Boom, Susanne C and Eikenboom, Ellis and Wagner, Anja and van Veghel-Plandsoen, Monique M and Geeven, Geert and Beverloo, Berna and van Rij, Caroline M and Verdijk, Robert M and Naus, Nicole C and Bagger, Mette M and Kiilgaard, Jens F and de Klein, Annelies and Brosens, Erwin and Kiliç, Emine},
  title = {Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma},
  journal = {Investigative Opthalmology & Visual Science},
  year = {2024},
  doi = {10.1167/iovs.65.2.11}
}
Start for free →